Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 429

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 429
---
      ​        ​   ​                ​   ​   ​      ​        ​   ​                ​
Ziritaxestat                                     ​   ​          666,967   ​   ​      ​        ​   ​          666,967   ​   ​      ​        ​   ​          666,967
Filgotinib (1)                                   ​   ​        1,372,178   ​   ​      9,466    ​   ​        1,381,644   ​   ​      10,604   ​   ​        1,392,248
Drug discovery platform (10 years)               ​   €        2,300,203   ​   €      674      ​   €        2,300,876   ​   €      45       ​   €        2,300,921
​                                                ​   ​                ​   ​   ​      ​        ​   ​                ​   ​   ​      ​        ​   ​                ​
​
(1) With regard to the additional consideration received as a result of the Option, License and Collaboration agreement (July 14, 2019) allocated to the filgotinib performance obligation, we assumed the existence of a significant financing component estimated to €44.5 million as of December 31, 2019 reflecting the time value of money on the estimated recognition period. This financing component was reassessed to €58.7 million on December 31, 2022, to €39.8 million on December 31, 2023 and to €39.3 million on January 31, 2024, the date of the transfer of the contract to Alfasigma.CLINICAL COLLABORATION AGREEMENT WITH ADAPTIMMUNE
On May 30, 2024, we entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune’s next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using our decentralized cell manufacturing platform. Under the terms of the Collaboration and Exclusive License Agreement, we paid an upfront exclusivity payment of $70.0 million and $15.0 million in R&D funding to Adaptimmune at signing of the collaboration agreement on May 30, 2024. A further $15.0 million in R&D funding will follow subject to the start of dosing in the proof-of-concept trial.